2 Information about solriamfetol

Marketing authorisation indication

2.1 Solriamfetol (Sunosi, Jazz Pharmaceuticals) is indicated 'to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for solriamfetol.


2.3 The list price for solriamfetol is £177.52 for a 75‑mg 28‑day pack and £248.64 for a 150‑mg 28‑day pack (excluding VAT; BNF online accessed September 2021). The company has a commercial arrangement, which would have applied if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)